G1 Therapeutics (GTHX) Given “Buy” Rating at Cowen

G1 Therapeutics (NASDAQ:GTHX)‘s stock had its “buy” rating reissued by investment analysts at Cowen in a report issued on Sunday.

A number of other analysts have also recently weighed in on GTHX. BidaskClub raised shares of G1 Therapeutics from a “sell” rating to a “hold” rating in a research report on Saturday, November 3rd. Zacks Investment Research raised shares of G1 Therapeutics from a “sell” rating to a “hold” rating in a research report on Wednesday, August 8th. Needham & Company LLC decreased their price objective on shares of G1 Therapeutics from $76.00 to $74.00 and set a “buy” rating for the company in a research report on Thursday. JPMorgan Chase & Co. upped their price objective on shares of G1 Therapeutics from $58.00 to $63.00 and gave the company an “overweight” rating in a research report on Friday, August 10th. Finally, BTIG Research started coverage on shares of G1 Therapeutics in a research report on Monday, September 10th. They issued a “buy” rating and a $80.00 price objective for the company. Two analysts have rated the stock with a hold rating and six have issued a buy rating to the company. The stock presently has a consensus rating of “Buy” and a consensus price target of $74.00.

Get G1 Therapeutics alerts:

Shares of G1 Therapeutics stock opened at $45.67 on Friday. G1 Therapeutics has a twelve month low of $18.03 and a twelve month high of $69.57. The firm has a market cap of $1.44 billion, a P/E ratio of -12.79 and a beta of 1.16.

G1 Therapeutics (NASDAQ:GTHX) last announced its quarterly earnings results on Wednesday, November 7th. The company reported ($0.59) earnings per share for the quarter, topping analysts’ consensus estimates of ($0.67) by $0.08. As a group, analysts anticipate that G1 Therapeutics will post -2.64 earnings per share for the current year.

In other G1 Therapeutics news, VP Jennifer K. Moses sold 750 shares of the company’s stock in a transaction dated Wednesday, September 5th. The shares were sold at an average price of $59.60, for a total value of $44,700.00. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. Also, SVP Terry L. Murdock sold 3,519 shares of the company’s stock in a transaction dated Tuesday, September 4th. The shares were sold at an average price of $59.98, for a total transaction of $211,069.62. The disclosure for this sale can be found here. Over the last three months, insiders sold 66,583 shares of company stock valued at $3,483,971. 15.92% of the stock is currently owned by corporate insiders.

A number of large investors have recently bought and sold shares of GTHX. Great West Life Assurance Co. Can lifted its position in shares of G1 Therapeutics by 148.3% during the second quarter. Great West Life Assurance Co. Can now owns 2,612 shares of the company’s stock worth $113,000 after purchasing an additional 1,560 shares during the last quarter. Cubist Systematic Strategies LLC lifted its position in shares of G1 Therapeutics by 484.5% during the first quarter. Cubist Systematic Strategies LLC now owns 2,794 shares of the company’s stock worth $104,000 after purchasing an additional 2,316 shares during the last quarter. Ladenburg Thalmann Financial Services Inc. lifted its position in shares of G1 Therapeutics by 44.4% during the first quarter. Ladenburg Thalmann Financial Services Inc. now owns 3,900 shares of the company’s stock worth $144,000 after purchasing an additional 1,200 shares during the last quarter. Strs Ohio lifted its position in shares of G1 Therapeutics by 78.3% during the second quarter. Strs Ohio now owns 4,100 shares of the company’s stock worth $178,000 after purchasing an additional 1,800 shares during the last quarter. Finally, WINTON GROUP Ltd bought a new position in shares of G1 Therapeutics during the third quarter worth about $218,000. 69.09% of the stock is owned by institutional investors.

About G1 Therapeutics

G1 Therapeutics, Inc, a clinical-stage biopharmaceutical company, focuses on the discovery, development, and commercialization of novel small molecule therapeutics for the treatment of patients with cancer in the United States. It is developing trilaciclib, an intravenous cyclin-dependent kinases (CDK) 4/6 inhibitor that is in Phase 1b/2a clinical trials for patients with small cell lung cancer, as well as Phase 2 clinical trial for patients with first-/second-/third-line metastatic triple-negative breast cancer; G1T38, an oral CDK4/6 inhibitor that is Phase 1b/2a clinical trials for the treatment of breast cancer; and G1T48, an oral selective estrogen receptor degrader, which is in preclinical development.